CytoAgents Overview
- Year Founded
-
2018
- Status
-
Private
- Employees
-
10
- Latest Deal Type
-
Later Stage VC
- Latest Deal Amount
-
$100K
- Investors
-
15
CytoAgents General Information
Description
Developer of pharmaceutical drugs designed to treat cytokine release syndrome. The company's drugs develop a broadly accessible treatment for multiple indications of high unmet need, including oncology CAR-T cell therapy, COVID-19, and respiratory epidemics, enabling physicians to effectively treat patients suffering from CRS through a novel approach by calming the natural immune response to a multi-organ disease.
Contact Information
Website
cytoagents.comCorporate Office
- 100 South Commons
- Suite 102
- Pittsburgh, PA 15212
- United States
Corporate Office
- 100 South Commons
- Suite 102
- Pittsburgh, PA 15212
- United States
CytoAgents Timeline
CytoAgents Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 12. Later Stage VC | 20-Jun-2025 | $100K | Completed | Generating Revenue | ||
| 11. Grant | 25-Sep-2024 | Completed | Clinical Trials - Phase 1 | |||
| 10. Later Stage VC | 10-Oct-2023 | Completed | Clinical Trials - Phase 1 | |||
| 9. Later Stage VC (Series A2) | 03-May-2023 | Completed | Clinical Trials - Phase 1 | |||
| 8. Early Stage VC (Series A1) | 02-Aug-2021 | Completed | Clinical Trials - Phase 1 | |||
| 7. Accelerator/Incubator | 04-Apr-2021 | Completed | Clinical Trials - Phase 1 | |||
| 6. Grant | 10-Mar-2021 | Completed | Clinical Trials - Phase 1 | |||
| 5. Grant | 06-Mar-2021 | Completed | Clinical Trials - Phase 1 | |||
| 4. Early Stage VC (Series A1) | 07-Jul-2020 | $250K | $3.75M | Completed | Clinical Trials - Phase 1 | |
| 3. Grant | 13-May-2020 | $1.6M | $3.5M | Completed | Clinical Trials - Phase 1 |
CytoAgents Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A2 | ||||||||
| Series A1 |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
CytoAgents Comparisons
Industry
Financing
Details
CytoAgents Competitors (38)
One of CytoAgents’s 38 competitors is Inovio Pharmaceuticals, a Corporation company based in Plymouth Meeting, PA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Inovio Pharmaceuticals | Corporation | Plymouth Meeting, PA | ||||
| Rein Therapeutics | Formerly VC-backed | Austin, TX | ||||
| Mesoblast | Corporation | Melbourne, Australia | ||||
| Oncoinvent (Acquired) | Formerly PE-Backed | Oslo, Norway | ||||
| Gangagen Biotechnologies | Venture Capital-Backed | Bangalore, India |
CytoAgents Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
CytoAgents Patents
CytoAgents Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026117685-A1 | Chimeric antigen receptor (car) t-cell adjuvant therapies | Pending | 27-Nov-2024 | ||
| US-20250368611-A1 | Method for preparing beraprost 314-d sodium | Pending | 30-May-2024 | ||
| WO-2025250828-A1 | Method for preparing beraprost 314-d sodium | Pending | 30-May-2024 | ||
| AU-2023280417-A1 | Chimeric antigen receptor (car) t-cell adjuvant therapies | Pending | 31-May-2022 | ||
| EP-4531832-A2 | Chimeric antigen receptor (car) t-cell adjuvant therapies | Pending | 31-May-2022 | A61K31/5585 |
CytoAgents Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
CytoAgents Investors (15)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Penn Cove Group | Corporation | Minority | ||
| Lehigh Valley Angel Investors | Angel Group | Minority | ||
| Mountain State Capital | Venture Capital | Minority | ||
| AlphaLab Health | Accelerator/Incubator | Minority | ||
| National Institute for Allergy and Infectious Disease | Government |
CytoAgents FAQs
-
When was CytoAgents founded?
CytoAgents was founded in 2018.
-
Where is CytoAgents headquartered?
CytoAgents is headquartered in Pittsburgh, PA.
-
What is the size of CytoAgents?
CytoAgents has 10 total employees.
-
What industry is CytoAgents in?
CytoAgents’s primary industry is Drug Discovery.
-
Is CytoAgents a private or public company?
CytoAgents is a Private company.
-
What is CytoAgents’s current revenue?
The current revenue for CytoAgents is .
-
How much funding has CytoAgents raised over time?
CytoAgents has raised $38.6M.
-
Who are CytoAgents’s investors?
Penn Cove Group, Lehigh Valley Angel Investors, Mountain State Capital, AlphaLab Health, and National Institute for Allergy and Infectious Disease are 5 of 15 investors who have invested in CytoAgents.
-
Who are CytoAgents’s competitors?
Inovio Pharmaceuticals, Rein Therapeutics, Mesoblast, Oncoinvent (Acquired), and Gangagen Biotechnologies are some of the 38 competitors of CytoAgents.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
